Physiomics Share Price (PYC)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Physiomics Plc	LSE:PYC	London	Ordinary Share	GB00BDR6W943	ORD 0.4P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	-0.10p	-2.44%	4.00p	1,469,274	13:15:34

Bid Price		Offer Price	High Price	Low Price	Open Price
3.90p		4.10p	4.10p	3.95p	4.10p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Health Care Equipment & Services	0.43	-0.26	-0.31		2.9

Related Shares
Smith & Nephew (SN.), NMC Health (NMC), Microemissive Displays (MED), Widecells (WDC)

Physiomics (PYC) Latest News

Physiomics News

Date	Time	Source	Headline
15/10/2018	12:00	UKREG	Physiomics PLC Dispatch of Annual Report and Shareholder Circular
08/10/2018	08:55	ALNC	Physiomics Annual Loss Halves, Revenue Doubles As New Momentum Emerges
08/10/2018	06:43	ALNCF	Alliance News Flash Headline
08/10/2018	06:00	UKREG	Physiomics PLC Final Results for the Year Ended 30 June 2018
09/8/2018	09:46	ALNC	Physiomics Wins GBP55,000 Contract With European Biotech Firm
09/8/2018	06:01	UKREG	Physiomics PLC Contract award
02/7/2018	12:57	RNSNON	Physiomics PLC Physiomics Expands Technical Team
21/6/2018	08:17	ALNC	Physiomics Expects Annual Loss To Be "Materially Reduced"
21/6/2018	06:00	UKREG	Physiomics PLC Trading Update
11/6/2018	15:05	RNSNON	Physiomics PLC Updated Website

More Physiomics News

Physiomics Takeover Rumours

Physiomics (PYC) Share Charts

1 Year Physiomics Chart

1 Month Physiomics Chart

Intraday Physiomics Chart

Physiomics (PYC) Discussions and Chat

Physiomics Forums and Chat

Date	Time	Title	Posts
15/11/2018	11:13	Physiomics - Cancer Treatment tech firm working with Merck + Oxford Uni	4,040
05/2/2018	09:02	Physiomics with Charts & News	13,702
31/1/2018	08:34	PHYSIOMICS plc Virtual Tumor platform	4,933
01/12/2017	19:18	RGP NEXT MULTI BAGGER TODAY 50p	4
01/12/2017	07:35	Timbeeerrr back to reality	-

Add a New Thread

Physiomics (PYC) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
15:54:46	4.08	25,000	1,020.00	O
15:51:42	4.08	30,000	1,224.00	O
15:34:15	4.04	112,000	4,520.32	O
14:07:49	3.93	25,000	982.50	O
13:37:34	4.04	56,715	2,289.02	O

View all Physiomics trades in real-time

Physiomics (PYC) Top Chat Posts

Date	Subject
16/11/2018 08:20	Physiomics Daily Update: Physiomics Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker PYC. The last closing price for Physiomics was 4.10p. Physiomics Plc has a 4 week average price of 3.80p and a 12 week average price of 3.65p. The 1 year high share price is 32p while the 1 year low share price is currently 0.98p. There are currently 71,910,394 shares in issue and the average daily traded volume is 323,596 shares. The market capitalisation of Physiomics Plc is £2,876,415.76. Read Full Thread Reply
06/9/2018 23:30	davevt: No you're missing my point. Think of the mid point as a flag on a rope constantly being pulled back and forth. The price you see on a site isn't live, it's lagged and delayed. The mid point price is constantly moving. So when you see a buy or sell reported, it's delayed, and it can simply be at the time of reporting the mid point as moved, the buy price is now below the mid point and 'reported as a sell'. It makes no difference what so ever. If the share price was 4 for instance, and then the bid was put up to 4.5 and an ask of 5, and all the trades that day were sells, the share price would go up would it not? Once again, it matters not if it's a buy or a sell, it's a TRADE, at a price. Read Full Thread Follow Reply
10/6/2018 14:31	pwhite73: OBD The current share price does not represent or misrepresent any value. The current share price is where mug punters are buying in order to support the next placing. The value of an AIM company and its share price completely divorced about 5 years ago. When was the last time you heard the term Price Earnings Ratio applied to an AIM stock. It cannot be that PYC was worth 32p per share in December 2017 valuing the company at £19 million and today the placing has valued the same company at just £2.8 million. Where has £16 million of value disappeared to in the space of seven months. You may not know where the share price will be in one years time but I certainly do. It will be back to 1p and this time it will stay there because mug punters are not going to be fooled again (he thinks!!). I have stated before and I'll say so again if it had not been for the November 2017 frenzy I believe PYC would have sought to exit from the AIM. Read Full Thread Follow Reply
10/6/2018 12:40	guss: For a more balanced view of the recent rise and fall of the share price I always read PWhites comments as they appear to me as well researched, polite and intelligent comments, always welcomed, but in this case not completely accurate. My experience of PYC over the past ten years, I think, it sure seems like that: I have profited in 3 out of the last 4 emotional price rises and missed the the boat at least once. Just before Christmas I looked at my 100,000 PYC shares, they had cost me over £7000 due to averaging down over the years but they were only worth £900. I considered cutting my loses and taking the £900 to spend on Christmas, or adding another £900 to the pot and doubling my holding. Luckily, and sadly, I did nothing. A week or so later the share price had gone from 0.9p to 32p. Having been in the red for 99% of the time that I held these shares I sold some of them at 12p ish more at 23p on the way up and then at 18p on the way down and then finally, after a few days of pondering if I should buy more, I sold the last of my holding at about 7p. Maybe I’m one of the lucky ones but I had no problem selling, they were gobbled up and I received £24k approx from the sale, although this did include my original stake which to be honest I had written off. I’m still watching these but I don’t want to be locked in for another 10 years, not with £7k worth anyway. If they do drop down to below 2p I might chuck a couple of grand at them. I think PWhite is probably right about the AIM way of funding a company, as close to a scam as you can get. But you can sell on a rise, for whatever reason, at least I did 😁 Read Full Thread Follow Reply
22/4/2018 13:04	the stigologist: PYC Physiomics (Share Price 6p ; Shares o/s 58m ; Mkt Cap £3.5m) On November 30th 2017 the ex-Founder of Physiomics made the following points in a long post in which he also claimed he believed PYC should be worth over 100p+ Collaborations with major pharmas have been constrained whilst the models are perfected and due to the secretive nature of all pharmas who generally speaking do not want to share data. The latest contract has dramatically increased the visibility of what PYC do and do best and will encourage a raft of Biotech analysts to write it up as more contracts are announced PYC is striving to personalised medicine The HOLY GRAIL with tremendous Social and Financial Implications. htTp://uk.advfn.com/cmn/fbb/thread.php3?id=31109702&from=3710 Since then the Physiomics management have on a number of occasions talked about Personalised Medicine, Cloud technology, AI (Artificial Intelligence) e.g. Interim Results February 2018 hTtps://www.investegate.co.uk/physiomics-plc--pyc-/rns/interim-results-statement/201802190700021669F/ "We believe that the advent of more powerful computing solutions, including cloud-based technologies and AI and their increasing adoption within the life sciences industry is leading to a resurgence of interest in rational drug design and in the use of modelling more generally in the R&D process." ... "This grant project, focused on the personalisation of oesophageal cancer treatment, has driven insights that may be integrated into our core Virtual Tumour offering and will also be the subject of thought capital that will be exploited over the course of this calendar year at industry conferences and through the publication of scientific papers in order to garner further interest from the drug research community. Finally, the ideas generated by this project have the potential to be taken forward in a further personalised medicine project for which the Company is currently seeking funding." Having presented 'successfully' last week at the AACR conference in Chicago,US, this coming week they will present on Tuesday 24th April 2018 at BioTrinity in the UK (Europe's leading Investment and Partnering conference for the BioPharma industry). Following that their previous funding partners the Government Innovate UK body will be launching a Personalised Medicine investment accelerator looking to invest £0.5m-1.5m in projects run by SMEs. hTtps://www.eventbrite.co.uk/e/leveraging-publicprivate-investment-tickets-44180316516 Now clearly a £3m company like Physiomics winning a big funding contract like that would be both an immense validation of their technology and approach but also fund their in a NON-DILUTIVE manner for many years. It's interesting that the UK Government is funding SMEs to tackle the Holy Grail of Personalised Medicine but there are other massive AI companies involved who could I suggest partner with Physiomics. Imagine £3m Physiomics announcing a deal with Jeff Bezos' $1bn+ cancer detection/personalised medicine start-up/roll-up Grail or how about with Google's UK AI specialist DeepMind (which they bought for $500m) and has an operation called DeepMind Health looking to work with Academics and the NHS for cancer detection/personalised medicine. This is something the market has not considered as of yet because they still see PYC as simply being a Company that will have biotechs and Pharmas as potential customers. htTps://theconversation.com/deepmind-can-we-ever-trust-a-machine-to-diagnose-cancer-88707 htTps://healthitanalytics.com/news/cancer-detection-company-gets-900m-from-pharma-vc-investors "GRAIL, Inc., a precision medicine and life sciences company aiming to develop new very early detection techniques for cancer, has attracted more than $900 million in investment capital from some of the most well-known names in pharmaceutical sales and development. Bristol-Myers Squibb, Celgene, Merck, and Johnson & Johnson Innovations have joined with other strategic investors, including Amazon’s Jeff Bezos and McKesson Ventures, to contribute hundreds of millions to the company’s financial future. “We envision a global community that benefits from early-stage cancer detection where fewer individuals face the anguish of late-stage diagnosis and devastating outcomes,” said Jeff Huber, GRAIL’s Chief Executive Officer. “I believe that GRAIL’s approach leveraging high-intensity sequencing, population-scale clinical studies, and state of the art computer science and data science is unparalleled in the field of cancer detection." Read Full Thread Follow Reply
19/4/2018 18:08	the stigologist: Now get a load of this. Start researching DeepMind Health and GRAIL before next week ! ------------------------------------------------------------------------------------ PYC Physiomics (Share Price 6p ; Shares o/s 58m ; Mkt Cap £3.5m) On November 30th 2017 the ex-Founder of Physiomics made the following points in a long post in which he also claimed he believed PYC should be worth over 100p+ Collaborations with major pharmas have been constrained whilst the models are perfected and due to the secretive nature of all pharmas who generally speaking do not want to share data. The latest contract has dramatically increased the visibility of what PYC do and do best and will encourage a raft of Biotech analysts to write it up as more contracts are announced PYC is striving to personalised medicine The HOLY GRAIL with tremendous Social and Financial Implications. htTp://uk.advfn.com/cmn/fbb/thread.php3?id=31109702&from=3710 Since then the Physiomics management have on a number of occasions talked about Personalised Medicine, Cloud technology, AI (Artificial Intelligence) e.g. Interim Results February 2018 hTtps://www.investegate.co.uk/physiomics-plc--pyc-/rns/interim-results-statement/201802190700021669F/ "We believe that the advent of more powerful computing solutions, including cloud-based technologies and AI and their increasing adoption within the life sciences industry is leading to a resurgence of interest in rational drug design and in the use of modelling more generally in the R&D process." ... "This grant project, focused on the personalisation of oesophageal cancer treatment, has driven insights that may be integrated into our core Virtual Tumour offering and will also be the subject of thought capital that will be exploited over the course of this calendar year at industry conferences and through the publication of scientific papers in order to garner further interest from the drug research community. Finally, the ideas generated by this project have the potential to be taken forward in a further personalised medicine project for which the Company is currently seeking funding." Having presented 'successfully' last week at the AACR conference in Chicago,US, this coming week they will present on Tuesday 24th April 2018 at BioTrinity in the UK (Europe's leading Investment and Partnering conference for the BioPharma industry). Following that their previous funding partners the Government Innovate UK body will be launching a Personalised Medicine investment accelerator looking to invest £0.5m-1.5m in projects run by SMEs. hTtps://www.eventbrite.co.uk/e/leveraging-publicprivate-investment-tickets-44180316516 Now clearly a £3m company like Physiomics winning a big funding contract like that would be both an immense validation of their technology and approach but also fund their in a NON-DILUTIVE manner for many years. It's interesting that the UK Government is funding SMEs to tackle the Holy Grail of Personalised Medicine but there are other massive AI companies involved who could I suggest partner with Physiomics. Imagine £3m Physiomics announcing a deal with Jeff Bezos' $1bn+ cancer detection/personalised medicine start-up/roll-up Grail or how about with Google's UK AI specialist DeepMind (which they bought for $500m) and has an operation called DeepMind Health looking to work with Academics and the NHS for cancer detection/personalised medicine. This is something the market has not considered as of yet because they still see PYC as simply being a Company that will have biotechs and Pharmas as potential customers. htTps://theconversation.com/deepmind-can-we-ever-trust-a-machine-to-diagnose-cancer-88707 htTps://healthitanalytics.com/news/cancer-detection-company-gets-900m-from-pharma-vc-investors "GRAIL, Inc., a precision medicine and life sciences company aiming to develop new very early detection techniques for cancer, has attracted more than $900 million in investment capital from some of the most well-known names in pharmaceutical sales and development. Bristol-Myers Squibb, Celgene, Merck, and Johnson & Johnson Innovations have joined with other strategic investors, including Amazon’s Jeff Bezos and McKesson Ventures, to contribute hundreds of millions to the company’s financial future. “We envision a global community that benefits from early-stage cancer detection where fewer individuals face the anguish of late-stage diagnosis and devastating outcomes,” said Jeff Huber, GRAIL’s Chief Executive Officer. “I believe that GRAIL’s approach leveraging high-intensity sequencing, population-scale clinical studies, and state of the art computer science and data science is unparalleled in the field of cancer detection." Read Full Thread Follow Reply
25/1/2018 11:14	the stigologist: Whilst it is quiet I thought I'd talk about how we should analyse and value a grant award. OXB recently got a £3m award from Govt/Innovate UK and it led to a mini spike in the share price. It was roughly 10% spike but £3m isn't as meaningful to a £300m Mkt Cap company as £0.25m would/should be to a £7m company like PYC. So how should we value an award to PYC. As a starting point I would suggest you use a 'market' PE for a software/tech company. I would suggest 20x is quite a conservative PE ratio for a Company like PYC. So if PYC get a £0.25m grant as a simple rule of thumb I'd multiply the E contribution by 20x to get the P value. So a £0.25m grant could/should be worth £5m in Market Cap terms to PYC However we also need to take into account that the Award provides further external validation to PYC. That has to have some value as well. It's harder to quantify this but I'd suggest the calibre of the partners (Oxford Uni / Oxford NHS / CRUK) all add significantly to the validation whilst the Government approval will add further premium on top. I would suggest a completely new Company coming to market as an IPO with such a project would be likely to be valued at £50m+. You only need to look at likes of ONC / OBD and Grail/Amazon for easy valuation comparitors on that front. Finally we should also consider the fact that such 'substantial non-dilutive funding' obviates the need for a placing/dilution. Given the fear of dilution amongst AIM investors (despite AIM being a supposed growth capital market !) this is a huge benefit. PYC have been remarkably disciplined in the last 15 months with ZERO placings. A further grant award would demonstrate conclusively that the Management of the finances and OUR 'equity' is being done judiciously and demand a premium on this AIM Management team. Thus I would expect all things considered the Market should value a £0.25m grant as being worth anywhere between £5-50m to PYC. Now if we get £0.5m... or £1m... whoosh Read Full Thread Follow Reply
09/1/2018 18:58	pwhite73: bellesimo PYC and PCGE are two different animals. PYC is an actual business PCGE is not (yet). As with all AIM stocks one has to separate the company from its listing and look at each on its own merits. PYC has been listed just before Noah built his ark. The company rakes up losses year after and it is questionable whether they have a commercial product. The directors wages are very modest compared to normal AIM executive pay. PYC does not play the stock market game. The company only makes announcements when required and never engages in one to one chats with shareholders outside of official meetings. You'll never find them on Proactive Investor or in any stock related media outlet. That is one of the major criticisms PI shareholders have leveled at the company for years. They never promote themselves outside of their industry. Prior to the update on 28/11/2017 the share price was trading at 1p to buy and this was after a consolidation about a year previously. The shares rushed up to 32p on BB speculation of multi-million contracts to be announced soon. The company was forced to issue a statement reiterating what they had said on 28/11/2017. Yet still some people refused to believe. All the froth has now died down and the shareprice is slowly but surely returning to from whence it came. There are still those that are saying "just wait until the next contract is announced". Even if one is announced PYC is not an early stage drug company that has a promising pipeline that can be sold on for millions. It is just a computer simulation company. It has nothing direct to sell to the general public it effectively relies on companies like Merck to adopt their software or their finished. Merck have companies like PYC over a barrel and they know it. Low volume is the normal order of the day with this company. On 27/11/2017 the day before the announcement there was just two trades, sells for 0.95p. The stock is still up by a whopping 650% from 28/11/2017. These are PIs still holding at prices in the mid teens but can't force themselves to sell. The market cap is about £4m. People think its cheap but its way overpriced for a company of this size, what it does and its prospects. These are just my views but I can see no reason why the stock will stay up 650%. The MM will drip drip short the stock down to about 2p - 3p and there it will stay. The other thing to bear in mind is that once the hot money is gone on an AIM stock it never really returns. Best of luck if you're holding. Read Full Thread Follow Reply
27/12/2017 11:08	margic: It's a good thing for the PYC share price that eyes have just come off this. As buyers start to return this can move very very quick before the herd arrive and when the herd arrive we spike. Signal to take profit and re-load as the herd exit with their losses and smaller profits. Hope to see this 10p+ before volumes really pick up. Keep watch as PYC can flash bang wallop! Read Full Thread Follow Reply
18/12/2017 09:06	the stigologist: Todays VAL Valirx news on VAL201 is also great news for PYC. Expect PYC share price to follow VAL up Read Full Thread Follow Reply
17/12/2017 11:28	margic: Great stuff mate and exactly what I was hoping for, you've opened the doors for everyone to take note and find where to search, it's research and posts like that, that can move a stock and why not, there new information to see for investors to start predicting a value and assessing the share price tools to decide if PYC represents value. Centara is a great example, I highly doubt PYC would be taken out for anywhere near that figure based on the past but then again, was it here I read the directors have been ousted? That might change the picture. The bod I remember for years ago were no good to share holders but then again, why would you want long term shareholders when you have a big big play behind closed doors and a shocking share price. Price makes the mouth water now. 11.5p circa £6mil market cap, in a market that can quickly add £50mil valve on anything material that investors can put there eyes on. Even the $32mil take over in 2012 coming out of the burst. More money is spent now and it doesn't take much for a big boy to offer £35-50mil for a small slice, it helps them balance their spending. As I understand it, big pharmacy have a budget quota that must be spent year on year on certain aspects of the business and accumulating businesses, investment partnerships, support and R&D have the highest budgets set in both fiscal cash and time. These budgets. I may be wrong but GSK used to spend like 1bil dollars min a year on failed products before the 80's even. Certainly with now only 57odd mil shares in circulation this is a good time for PYC. I'm sure they can prove the markets cap to £12-15mil and then raising money to boost the line will become comfortable. Unless a take over offer happens out of no where you'd have to expect PYC to place just over 100mil shares, but it's very possible they could secure £10-30mil doing that. Big money for them, not sure they've ever had that at their disposal. As always it will be down to the bod and how soon they want to make their money. Many old money directors have 50-75years for their plays to come good.Is there any key news expected from the faithful? How do you see the BOD moving the company going forward, has anyone meet them or heard them speak? Thanks for the informative stuff stig. I'm only just flirting back in the aim market, I'm a technical trader now with currency's but I do like the aim. It seems now is like 2007-2011 all over again. Rises do seem much bigger. A good start for me has been some of the oldies im familiar with have been squeezed almost to the max and everything is jumping like true penny stocks should.PYC for starters, great news, big share price jump, hype, 57 something mil shares £6mil value, same as always, jumped in with 3mil market cap, can always go £12-15mil outta now where £35-50mil on transformational news, and £100mil + on a well sourced city take over rumour or bid. Bid less likely in normal terms but then again, Takeovers in the Pharma game are normally as good if not better than the tech industry. Disney splashing out £34bil, for essentially parts of a business, imagine what big pharmacy made will pay to wrap a deal up quick. It's not a ramp but I do know if GSK want a business they think a rival will want, they make an offer that won't be matched to conduct a move super quick. If PYC was valued by a proper surveying team at say £65mil (figure I've come up with based off others) , and no one was interested then it's a 20mil offer for part. If other firms are interested it's £80mil+, if a major rival is sniffing, £150-180mil+ plus part retention, if they feel a rival will bid, they'll re-visit alternatives, if they believe PYC to be better than all the rest, then you could be actually looking £500mil + you get a bidding war on that, who knows from there. That's how I see it. Read Full Thread Follow Reply

Physiomics share price data is direct from the London Stock Exchange

add chat code

Your Recent History

LSE

SALV

Salvarx Gr..

LSE

CRAW

Crawshaw

LSE

VRE

VR Educati..

LSE

RMS

Remote Mon..

LSE

TST

Touchstar

LSE

GAMA

Gamma

LSE

KWS

Keywords

TSX

VRE

Vanguard F..

ASX

VRE

View Resou..

LSE

KAT

Katoro Gol..

LSE

SRO

Spitfire O..

TSX

KAT

Katanga Mi..

ASX

KAT

Katana Cap..

LSE

GWMO

Great West..

LSE

MILA

Mila Resou..

LSE

RLD

Richland R..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:31 V: D:20181116 23:33:38